darbepoetin alpha for the treatment of anemiain systemic mastocytosis

n/

"Molecular Detection of BCL2/IGH Rearrangement in Follicular Lymphoma in Low Resource Settings: A Phase III Diagnostic Accuracy Study"

n/

Pathology of Malaria

Malaria is an acute febrile illness that is caused by infection with Plasmodium spp. parasites. Malaria is a serious illness and sometimes it may be fatal resulting in mortality and morbidity. The clinical picture painted in patients with malarial infection occurs following the release of the merozoites into the bloodstream following the rupture of infected red cells. In the infection with the P. falciparum, the commonest form affecting humans, all stages of red cells are infected making the infection quite severe as compared to infection with other species which infects the old and young red cells only which contributes to a small percentage of red cells. In this chapter, the Authors review the current knowledge about Malaria epidemiology, pathogenesis and anatomic pathology. The diverse clinical pictures as well as the association with genetic conditions and diseases are discussed

Introductory Chapter: Malaria in 2022 – Promises and Unmet Needs

In this chapter were described: biological cycle of Plasmodia and diagnostic assays for malaria: microscopic examination, Rapid Diagnostic Test (RDT) based on antigen, Indirect Fluorescent Antibody Test (IFA test), and also, recently introduced and accepted, the nucleic-acid detection method by PCR or LAMP technologie

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.

The therapeutic landscape of chronic myeloid leukemia (CML) has changed dramatically in the last decade. In particular, the availability of imatinib mesylate, a tyrosine kinase inhibitor targeting BCR-ABL, has led to profound and durable remissions in the majority of patients. However, a couple of issues have emerged and partially obscured this scenario. First, it has become clear that a significant proportion of patients either present with primary resistance to imatinib or develop secondary resistance sooner or later during treatment. Second, although the drug is generally well tolerated, a percentage of patients eventually cease treatment because of toxicity. Bearing this in mind, second-generation tyrosine kinase inhibitors have been introduced, including nilotinib. Phase I and II studies indicate remarkable activity for this compound in CML cases resistant to imatinib, including some of those carrying BCR-ABL1 mutants. More recently, two Phase II studies and a III randomized Phase clinical trial demonstrated the superiority of nilotinib compared with imatinib in terms of complete cytogenetic and major molecular responses, which are two relevant surrogate measures of long-term survival in CML. In this paper, we review the most relevant data on nilotinib as first-line treatment for CML, and discuss the rationale for its routine use, as well as some possible future perspectives for CML patients